MyMedR

Displaying all 3 publications

Abstract:

Sort:

Evaluating an economic application of renewable generated hydrogen: A way forward for green economic performance and policy measures

Wu B, Zhai B, Mu H, Peng X, Wang C, Patwary AK

Environ Sci Pollut Res Int, 2022 Feb;29(10):15144-15158.
PMID: 34628612 DOI: 10.1007/s11356-021-16770-6

Energy security and environmental measurements are incomplete without renewable energy; therefore, there is a dire need to explore new energy sources. Hence, this study aimed to measure the wind power potential to generate renewable hydrogen (H2), including its production and supply cost. This study used first-order engineering model and net present value to measure the levelized cost of wind-generated renewable hydrogen by using the data source of the Pakistan Meteorological Department and State Bank of Pakistan. Results showed that the use of surplus wind and renewable hydrogen energy for green economic production is suggested as an innovative project option for large-scale hydrogen use. The key annual running expenses for hydrogen are electricity and storage costs, which have a significant impact on the costs of renewable hydrogen. The results also indicated that the project can potentially cut carbon dioxide (CO2) pollution by 139 million metric tons and raise revenue for wind power plants by US$2998.52 million. The renewable electrolyzer plants avoided CO2 at a rate of US$24.9-36.9/ton under baseload service, relative to US$44.3/ton for the benchmark. However, in the more practical mid-load situation, these plants have significant benefits. Further, the wind-generated renewable hydrogen delivers 6-11% larger annual rate of return than the standard CO2 catch plant due to their capacity to remain running and supply hydrogen to the consumer through periods of plentiful wind and heat. Also, the measured levelized output cost of hydrogen (LCOH) was US$6.22/kgH2, and for the PEC system, it was US$8.43/kgH2. Finally, it is a mutually agreed consensus among environmental scientists that the integration of renewable energy is the way forward to increase energy security and environmental performance by ensuring uninterrupted clean and green energy. This application has the potential to address Pakistan's urgent issues of large-scale surplus wind- and solar-generated energy, as well as rising energy demand.
Retraction Note: Evaluating an economic application of renewable generated hydrogen: A way forward for green economic performance and policy measures

Wu B, Zhai B, Mu H, Peng X, Wang C, Patwary AK

Environ Sci Pollut Res Int, 2024 Jul;31(33):46097.
PMID: 38970633 DOI: 10.1007/s11356-024-34313-7
Fulltext Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region

Qin X, Rui J, Xia Y, Mu H, Song SH, Raja Aziddin RE, et al.

Ann Lab Med, 2018 Mar;38(2):85-94.
PMID: 29214751 DOI: 10.3343/alm.2018.38.2.85

BACKGROUND: The immunosuppressant drugs (ISDs), tacrolimus and cyclosporine, are vital for solid organ transplant patients to prevent rejection. However, toxicity is a concern, and absorption is highly variable across patients; therefore, ISD levels need to be precisely monitored. In the Asia-Pacific (APAC) region, tacrolimus and cyclosporine concentrations are typically measured using immunoassays. The objective of this study was to assess the analytical performance of Roche Elecsystacrolimus and cyclosporinee electrochemiluminescence immunoassays (ECLIAs).
METHODS: This evaluation was performed in seven centers across China, South Korea, and Malaysia. Imprecision (repeatability and reproducibility), assay accuracy, and lot-to-lot reagent variability were tested. The Elecsys ECLIAs were compared with commercially available immunoassays (Architect, Dimension, and Viva-E systems) using whole blood samples from patients with various transplant types (kidney, liver, heart, and bone marrow).
RESULTS: Coefficients of variation for repeatability and reproducibility were ≤5.4% and ≤12.4%, respectively, for the tacrolimus ECLIA, and ≤5.1% and ≤7.3%, respectively, for the cyclosporine ECLIA. Method comparisons of the tacrolimus ECLIA with Architect, Dimension, and Viva-E systems yielded slope values of 1.01, 1.14, and 0.897, respectively. The cyclosporine ECLIA showed even closer agreements with the Architect, Dimension, and Viva-E systems (slope values of 1.04, 1.04, and 1.09, respectively). No major differences were observed among the different transplant types.
CONCLUSIONS: The tacrolimus and cyclosporine ECLIAs demonstrated excellent precision and close agreement with other immunoassays tested. These results show that both assays are suitable for ISD monitoring in an APAC population across a range of different transplant types.

Filters

Please provide feedback to Administrator ([email protected])

External Links